8-K//Current report
Vivani Medical, Inc. 8-K
Accession 0001753926-26-000194
$VANICIK 0001266806operating
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 4:11 PM ET
Size
1.4 MB
Accession
0001753926-26-000194
Research Summary
AI-generated summary of this filing
Vivani Medical Announces $4.5M Equity Offerings
What Happened
- Vivani Medical, Inc. (VANI) filed an 8-K (Jan 27, 2026) announcing two equity financings entered into on January 25, 2026: a private placement and a registered direct offering to raise approximately $4.5 million in gross proceeds.
- The private placement: a Share Purchase Agreement with an entity affiliated with Gregg Williams (Chairman) to buy 1,351,351 shares at $1.48 per share (last reported sale price on Jan 23, 2026), raising about $2.0 million. No warrants or discounts were issued and no placement agent fees were paid for this private sale. The shares are being issued under Rule 506 of Regulation D.
- The registered offering: a Placement Agency Agreement with ThinkEquity LLC to sell 1,689,200 shares in a registered direct offering, expected to raise about $2.5 million before placement agent fees and expenses. The Company agreed to pay the agent a 7.0% cash fee and reimburse up to $125,000 of the agent’s expenses. Directors and officers entered into 60‑day lock-up agreements following the offering’s closing.
- The filing includes a legal opinion from Goodwin Procter LLP and a press release dated January 25, 2026 (filed as Exhibit 99.1).
Key Details
- Private placement: 1,351,351 shares at $1.48/share → ≈ $2.0M gross proceeds.
- Registered offering: 1,689,200 shares → ≈ $2.5M gross proceeds (before fees).
- Placement agent fees for the registered offering: 7.0% of proceeds + up to $125,000 reimbursable expenses.
- Lock-up: Company directors and officers agreed to a 60‑day post-closing lock-up for their securities.
Why It Matters
- The combined financings provide Vivani approximately $4.5M in fresh capital, which can help fund operations, development, or other corporate needs. However, issuing new shares will dilute existing shareholders’ ownership.
- The registered offering’s 7% fee and reimbursable expenses will reduce net proceeds. The private placement involved an affiliate of the chairman, which signals insider participation but also is an insider-related transaction that investors should note.
- The 60‑day lock-up limits immediate insider selling after the registered offering closes, which can help near-term market stability. Investors should monitor subsequent SEC filings for the actual closing, final net proceeds, and any updates on use of proceeds.
Documents
- 8-Kvani-20260125.htmPrimary
8-K
- EX-101.DEFvani-20260125_def.xml
DEFINITION
- EX-101.PREvani-20260125_pre.xml
PRESENTATION
- EX-101.CALvani-20260125_cal.xml
CALCULATION
- EX-101.LABvani-20260125_lab.xml
LABEL
- EX-101.SCHvani-20260125.xsd
SCHEMA
- EX-5.1ex51_1.htm
EXHIBIT 5.1
- EX-10.1ex101_2.htm
EXHIBIT 10.1
- EX-10.2ex102_3.htm
EXHIBIT 10.2
- EX-99.1ex991_4.htm
EXHIBIT 99.1
- GRAPHICccf5dbede8ab0215a0ea.jpg
GRAPHIC
- XMLR1.htm
IDEA: XBRL DOCUMENT
- XMLShow.js
IDEA: XBRL DOCUMENT
- XMLreport.css
IDEA: XBRL DOCUMENT
- XMLFilingSummary.xml
IDEA: XBRL DOCUMENT
- JSONMetaLinks.json
IDEA: XBRL DOCUMENT
- ZIP0001753926-26-000194-xbrl.zip
IDEA: XBRL DOCUMENT
- XMLvani-20260125_htm.xml
IDEA: XBRL DOCUMENT
Issuer
Vivani Medical, Inc.
CIK 0001266806
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001266806
Filing Metadata
- Form type
- 8-K
- Filed
- Jan 26, 7:00 PM ET
- Accepted
- Jan 27, 4:11 PM ET
- Size
- 1.4 MB